☆ 4.2 Editorial Material

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors

IMMUNOTHERAPY (2020)

Journal

IMMUNOTHERAPY

Volume 12, Issue 5, Pages 269-273

Publisher

FUTURE MEDICINE LTD

DOI: 10.2217/imt-2020-0067

Keywords

anti-CTLA-4; anti-PD-1; anti-PD-L1; cancer patients; COVID-19; immune checkpoint inhibitors; immunotherapy; SARS-CoV-2; tocilizumab; viral infection

Categories

Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.